

OSTEOPORE PRODUCT APPROVED FOR ADDITIONAL APPLICATIONS IN TAIWAN

27 March 2023: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a global leader in the manufacture of innovative regenerative implants that empower natural tissue regeneration, is pleased to announce it has secured Taiwanese regulatory approval for an additional application of its Osteomesh[®] product.

This development not only extends our presence in the Taiwanese market, but also represents a growth opportunity for the Company. Previously, Osteomesh[®] was approved in Taiwan for orbital (eye) area reconstruction. This new approval now enables its application in reconstruction procedures beyond the orbital area, extending into the craniofacial regions.

The expanded approval opens up market opportunity in the nasal bone area, which is one of the target segments for the Company. In addition to addressing functional issues, surgical treatment of the nasal bone area provides aesthetic relief for patients. Based on a survey conducted in 2021 (3,088 participants)¹, adjustments to the nasal structure is the fourth most common aesthetic procedure in Taiwan.

In addition to the Osteomesh[®] for orbital reconstruction, Osteopore now has the Osteomesh[®] for nasal bone repair to address various craniofacial surgical needs in Taiwan. Supplementing the market entry procedure, the Company will work with its distributors to obtain government reimbursement for relevant product lines. This will enable the products to be more accessible to a wider range of patients.

Osteopore Chief Executive Officer, Goh Khoon Seng said:

“We are thrilled to share this news, as it not only enhances our footprint in the Taiwanese market, but also highlights our dedication to revolutionising patients’ lives through innovative regenerative implants. Our aim is to work in tandem with our distributor to unlock growth opportunities for the Company.”

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

¹ <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627936/>

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.